What does this research mean for the field?

Rational design of structural features in GLP-1 analogs, such as N-terminal modifications and lipidation, fundamentally governs their receptor engagement, pharmacokinetics, and therapeutic efficacy. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To review the structural features of GLP-1 analogs that govern receptor binding, downstream signaling bias, and pharmacokinetic properties.

September 1, 2026Biomedical JournalOpen Access

Structural Overview of GLP-1 Analogs

View Full Paper

Ask AI

Bookmark

Authors

WVWijnand J.C. van der Velden AAAsta F. Andresen MRMette M. Rosenkilde

Discussion

Member takes

Overview

Narrative review synthesizes structural determinants governing GLP-1 analog pharmacokinetics and receptor signaling, highlighting rational design principles for next-generation incretin therapies.

Key Points

To review the structural features of GLP-1 analogs that govern receptor binding, downstream signaling bias, and pharmacokinetic properties.
Literature synthesis examining chemical modifications, including N-terminal edits, backbone stabilization, lipidation, and multi-receptor agonist frameworks.
N-terminal alterations confer resistance to enzymatic degradation by dipeptidyl peptidase-4, while C-terminal and backbone modifications stabilize peptide helicity to enhance GLP-1 receptor affinity.
Lipidation and albumin-binding moieties extend circulating half-life, providing the structural mechanism for sustained action in agents like liraglutide and semaglutide.
Sequence alterations modulate biased signaling between G protein activation and β-arrestin recruitment, informing computational design of emerging multi-incretin agonists.

Cite This Study

Velden et al. (2026) studied this question.

synapsesocial.com/papers/6aaa41c8561c8ccf3ff28554 https://doi.org/10.1016/j.bj.2026.101037

View Full Paper

Ask AI

Bookmark

September 1, 2026Biomedical JournalOpen Access

Structural Overview of GLP-1 Analogs

View Full Paper

Ask AI

Bookmark

Authors

WVWijnand J.C. van der Velden AAAsta F. Andresen MRMette M. Rosenkilde

Discussion

Member takes

Overview

Narrative review synthesizes structural determinants governing GLP-1 analog pharmacokinetics and receptor signaling, highlighting rational design principles for next-generation incretin therapies.

Key Points

To review the structural features of GLP-1 analogs that govern receptor binding, downstream signaling bias, and pharmacokinetic properties.
Literature synthesis examining chemical modifications, including N-terminal edits, backbone stabilization, lipidation, and multi-receptor agonist frameworks.
N-terminal alterations confer resistance to enzymatic degradation by dipeptidyl peptidase-4, while C-terminal and backbone modifications stabilize peptide helicity to enhance GLP-1 receptor affinity.
Lipidation and albumin-binding moieties extend circulating half-life, providing the structural mechanism for sustained action in agents like liraglutide and semaglutide.
Sequence alterations modulate biased signaling between G protein activation and β-arrestin recruitment, informing computational design of emerging multi-incretin agonists.

Cite This Study

Velden et al. (2026) studied this question.

synapsesocial.com/papers/6aaa41c8561c8ccf3ff28554 https://doi.org/10.1016/j.bj.2026.101037

View Full Paper

Ask AI

Bookmark